DMXL2
DmX-like protein 2
Also known as: DFNA71, DMXL2_HUMAN, KIAA0856, RC3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8TDJ6
- Gene
- DMXL2
- Ensembl
- ENSG00000104093
- Chromosome
- 15
- Canonical length
- 3036 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted membrane proteins, Transporters
OverviewNCBI Gene
This gene encodes a protein with 12 WD domains. Proteins with WD domains are involved in many functions including participation in signal transduction pathways. Participation of the encoded protein in regulation of the Notch signaling pathway has been demonstrated in vitro using several human cell lines (PMID:20810660). A gene encoding a similar protein is located on chromosome 5. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]
Canonical amino-acid sequenceUniProt
3036 residues, UniProt reviewed canonical sequence.
>Q8TDJ6|DMXL2
1 MHLHQVLTGA VNPGDNCYSV GSVGDVPFTA YGSGCDIVIL ANDFECVQII PGAKHGNIQV
61 SCVECSNQQG RIAASYGNAV CIFEPLGINS HKRNCQLKCQ WLKTGQFFLS SVTYNLAWDP
121 QDNRLLTATD SIQLWAPPGD DILEEEEEID NTVPPVLNDW KCVWQCKTSV SVHLMEWSPD
181 GEYFATAGKD DCLLKVWYPM TGWKSSIIPQ DHHEVKRRQS STQFSFVYLA HPRAVTGFSW
241 RKTSKYMPRG SVCNVLLTSC HDGVCRLWAE TLLPEDCLLG EQICETTTSS IASSLSHAGR
301 HKDRIQHALE TIHHLKNLRK GQRRSSVLVT HAELMPDQTA MHEVQRHISH HANALCHFHI
361 AASINPATDI PNVLVGTAFN VDDGNGGFVV HWLNNKEFHF TSSTEVFMHQ LRKLSDKQVD
421 HENDDADRED EEHSQEDRER GLHMKLDHDL SLDRESEAGT GSSEHEDGER EGSPRTYSRL
481 SVPMPLPTVL LDRKIETLLT EWNKNPDMLF TIHPVDGTFL VWHVKYLDEY NPGIFRQVQV
541 SFSSRIPVAF PSGDASSLSK NIMMYACINA TKDSHHTLLH QEGMSVGSPH GSQPHSRSHS
601 THMNILAPTV MMISKHIDGS LNQWAVTFAD KSAFTTVLTV SHKFRYCGHR FHLNDLACHS
661 VLPLLLTSSH HNALLTPELD CQWDSDNKLS RLMDPVKHIK GSSKQPLRNA ATRTFHDPNA
721 IYSELILWRV DPIGPLSYTG GVSELARINS LHTSAFSNVA WLPTLIPSYC LGTYCNSASA
781 CFVASDGKNL RLYQAVVDAR KLLDELSDPE SSKLIGEVFN IVSQQSTARP GCIIELDAIT
841 NQCGSNTQLL HVFQEDFIIG YKPHKEDMEK KETEIFFQPS QGYRPPPFSE KFFLVVIEKD
901 SNNNSILHMW HLHLKSVQAC LAKASEGASS ESLLSVPGQK NVDSSPETSP SVSPMPHSSS
961 IANLQTASKL ILSSRLVYSQ PLDLPESVEV IRATPSAGHL SSSSIYPVCL APYLVVTTCS
1021 DNKVRFWKCC MEANPECNKS DEKEIYHWKR WPLMNDEGED NSSTVSIVGR PVAVSCSYTG
1081 RLAVAYKQPI HHNGFVSKEF SMHVCIFECE STGGSEWVLE QTIHLDDLVK VGSVLDSRVS
1141 VDSNLFVYSK SDALLSKDRY LIPNIKHLVH LDWVSKEDGS HILTVGVGAN IFMYGRLSGI
1201 VTEQTNSKDG VAVITLPLGG SIKQGVKSRW VLLRSIDLVS SVDGTPSLPV SLSWVRDGIL
1261 VVGMDCEMHV YAQWKHAVKF GDTEADSSNA EEAAMQDHST FKSNMLARKS VVEGTAISDD
1321 VFCSPTVIQD GGLFEAAHVL SPTLPQYHPT QLLELMDLGK VRRAKAILSH LVKCIAGEVA
1381 IVRDPDAGEG TKRHLSRTIS VSGSTAKETV TVGKDGTRDY TEIDSIPPLP LYALLAADQD
1441 TSYRISEEST KIPQSYEDQT VSQPEDQYSE LFQIQDIPTD DIDLEPEKRE NKSKVINLSQ
1501 YGPAYFGQEH ARVLSSHLMH SSLPGLTRLE QMFLVALADT VATTSTELDE SRDKSCSGRD
1561 TLDECGLRYL LAMRLHTCLL TSLPPLYRVQ LLHQGVSTCH FAWAFHSEAE EELINMIPAI
1621 QRGDPQWSEL RAMGIGWWVR NINTLRRCIE KVAKASFQRN NDALDAALFY LSMKKKAVVW
1681 GLFRSQHDEK MTTFFSHNFN EDRWRKAALK NAFSLLGKQR FEQSAAFFLL AGSLKDAIEV
1741 CLEKMEDIQL AMVIARLYES EFETSSTYIS ILNQKILGCQ KDGSGFSCKR LHPDPFLRSL
1801 AYWVMKDYTR ALDTLLEQTP KEDDEHQVII KSCNPVAFSF YNYLRTHPLL IRRNLASPEG
1861 TLATLGLKTE KNFVDKINLI ERKLFFTTAN AHFKVGCPVL ALEVLSKIPK VTKTSALSAK
1921 KDQPDFISHR MDDVPSHSKA LSDGNGSSGI EWSNVTSSQY DWSQPIVKVD EEPLNLDWGE
1981 DHDSALDEEE DDAVGLVMKS TDAREKDKQS DQKASDPNML LTPQEEDDPE GDTEVDVIAE
2041 QLKFRACLKI LMTELRTLAT GYEVDGGKLR FQLYNWLEKE IAALHEICNH ESVIKEYSSK
2101 TYSKVESDLL DQEEMVDKPD IGSYERHQIE RRRLQAKREH AERRKSWLQK NQDLLRVFLS
2161 YCSLHGAQGG GLASVRMELK FLLQESQQET TVKQLQSPLP LPTTLPLLSA SIASTKTVIA
2221 NPVLYLNNHI HDILYTIVQM KTPPHPSIED VKVHTLHSLA ASLSASIYQA LCDSHSYSQT
2281 EGNQFTGMAY QGLLLSDRRR LRTESIEEHA TPNSSPAQWP GVSSLINLLS SAQDEDQPKL
2341 NILLCEAVVA VYLSLLIHAL ATNSSSELFR LAAHPLNNRM WAAVFGGGVK LVVKPRRQSE
2401 NISAPPVLSE DIDKHRRRFN MRMLVPGRPV KDATPPPVPA ERPSYKEKFI PPELSMWDYF
2461 VAKPFLPLSD SGVIYDSDES IHSDEEDDAF FSDTQIQEHQ DPNSYSWALL HLTMVKLALH
2521 NVKNFFPIAG LEFSELPVTS PLGIAVIKNL ENWEQILQEK MDQFEGPPPN YINTYPTDLS
2581 VGAGPAILRN KAMLEPENTP FKSRDSSAFP VKRLWHFLVK QEVLQETFIR YIFTKKRKQS
2641 EVEADLGYPG GKAKVIHKES DMIMAFSVNK ANCNEIVLAS THDVQELDVT SLLACQSYIW
2701 IGEEYDRESK SSDDVDYRGS TTTLYQPSAT SYSASQVHPP SSLPWLGTGQ TSTGASVLMK
2761 RNLHNVKRMT SHPVHQYYLT GAQDGSVRMF EWTRPQQLVC FRQAGNARVT RLYFNSQGNK
2821 CGVADGEGFL SIWQVNQTAS NPKPYMSWQC HSKATSDFAF ITSSSLVATS GHSNDNRNVC
2881 LWDTLISPGN SLIHGFTCHD HGATVLQYAP KQQLLISGGR KGHVCIFDIR QRQLIHTFQA
2941 HDSAIKALAL DPYEEYFTTG SAEGNIKVWR LTGHGLIHSF KSEHAKQSIF RNIGAGVMQI
3001 DIIQGNRLFS CGADGTLKTR VLPNAFNIPN RILDILLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DMXL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0
- Highest tissue expression
- 16 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 16 nTPM
- retina: 15 nTPM
- epididymis: 13 nTPM
- cerebral cortex: 11 nTPM
- appendix: 11 nTPM
- duodenum: 8.7 nTPM
Single-cell type
- monocytes: 733 nCPM
- neutrophils: 692 nCPM
- kupffer cells: 444 nCPM
- neutrophil progenitors: 364 nCPM
- monocyte progenitors: 331 nCPM
- macrophages: 286 nCPM
Immune cell
- classical monocyte: 2.8 nTPM
- non-classical monocyte: 2.7 nTPM
- intermediate monocyte: 2.2 nTPM
- neutrophil: 2.2 nTPM
- myeloid DC: 0.6 nTPM
- total PBMC: 0.4 nTPM
Brain region
- choroid plexus: 54 nTPM
- hippocampal formation: 53 nTPM
- cerebral cortex: 51 nTPM
- thalamus: 44 nTPM
- basal ganglia: 44 nTPM
- cerebellum: 42 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DMXL2.
Disease | AllUniProt
Conditions DMXL2 is implicated in, by any mechanism.
- Polyendocrine-polyneuropathy syndrome (PEPNS) MIM:616113
- Deafness, autosomal dominant, 71 (DFNA71) MIM:617605
- Developmental and epileptic encephalopathy 81 (DEE81) MIM:618663
Disease | GeneticClinVar
63 pathogenic / likely-pathogenic of 1,956 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Developmental and epileptic encephalopathy, 81
- Hearing loss, autosomal dominant 71
- DMXL2-related disorder
- Polyendocrine-polyneuropathy syndrome
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.16
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.37
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DMXL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DMXL2 as an antibody target. Whether an autoantibody or antibody against DMXL2 could matter depends on whether native DMXL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DMXL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DMXL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...